Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019
Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019
SUMMARY
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis (Psoriasis Vulgaris), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).
The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis (Psoriasis Vulgaris), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).
The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
- The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
Alkermes Plc
Anaveon AG
APT Therapeutics Inc
Bristol-Myers Squibb Co
Courier Therapeutics Inc
Mabtech Ltd
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
ALKS-4230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-92252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NARA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
Featured News & Press Releases
Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Nov 08, 2019: Alkermes announces new data from ALKS 4230 clinical development program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Nov 04, 2019: Alkermes to present data from ALKS 4230 clinical development program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 21, 2019: Alkermes announces clinical collaboration with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis
Jun 13, 2019: First-in-Human data presented from Phase 1a Study of NKTR-358, a novel t regulatory cell stimullator, at Annual European Congress of Rheumatology
Jun 12, 2019: Alkermes advances ALKS 4230 into monotherapy expansion Phase of ARTISTRY-1 in patients with renal cell carcinoma or melanoma
Jun 11, 2019: Nektar Therapeutics to host webcast conference call with immunology expert for analysts & investors during 2019 European Congress of Rheumatology (EULAR 2019)
Feb 26, 2019: Alkermes initiates clinical study of ALKS 4230 administered subcutaneously in patients with advanced solid tumors
Nov 06, 2018: Alkermes presents new data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours
Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
May 18, 2018: EMA review of Zinbryta confirms medicine’s risks outweigh its benefits
May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
Alkermes Plc
Anaveon AG
APT Therapeutics Inc
Bristol-Myers Squibb Co
Courier Therapeutics Inc
Mabtech Ltd
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
ALKS-4230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-92252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NARA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
Featured News & Press Releases
Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Nov 08, 2019: Alkermes announces new data from ALKS 4230 clinical development program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Nov 04, 2019: Alkermes to present data from ALKS 4230 clinical development program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 21, 2019: Alkermes announces clinical collaboration with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis
Jun 13, 2019: First-in-Human data presented from Phase 1a Study of NKTR-358, a novel t regulatory cell stimullator, at Annual European Congress of Rheumatology
Jun 12, 2019: Alkermes advances ALKS 4230 into monotherapy expansion Phase of ARTISTRY-1 in patients with renal cell carcinoma or melanoma
Jun 11, 2019: Nektar Therapeutics to host webcast conference call with immunology expert for analysts & investors during 2019 European Congress of Rheumatology (EULAR 2019)
Feb 26, 2019: Alkermes initiates clinical study of ALKS 4230 administered subcutaneously in patients with advanced solid tumors
Nov 06, 2018: Alkermes presents new data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours
Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
May 18, 2018: EMA review of Zinbryta confirms medicine’s risks outweigh its benefits
May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alkermes Plc, H2 2019
Pipeline by Anaveon AG, H2 2019
Pipeline by APT Therapeutics Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Courier Therapeutics Inc, H2 2019
Pipeline by Mabtech Ltd, H2 2019
Pipeline by Medicenna Therapeutics Corp, H2 2019
Pipeline by Nektar Therapeutics, H2 2019
Pipeline by Philogen SpA, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alkermes Plc, H2 2019
Pipeline by Anaveon AG, H2 2019
Pipeline by APT Therapeutics Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Courier Therapeutics Inc, H2 2019
Pipeline by Mabtech Ltd, H2 2019
Pipeline by Medicenna Therapeutics Corp, H2 2019
Pipeline by Nektar Therapeutics, H2 2019
Pipeline by Philogen SpA, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Alkermes Plc
Anaveon AG
APT Therapeutics Inc
Bristol-Myers Squibb Co
Courier Therapeutics Inc
Mabtech Ltd
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Alkermes Plc
Anaveon AG
APT Therapeutics Inc
Bristol-Myers Squibb Co
Courier Therapeutics Inc
Mabtech Ltd
Medicenna Therapeutics Corp
Nektar Therapeutics
Philogen SpA
